keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28516890/tocilizumab-in-the-treatment-of-patients-with-rheumatoid-arthritis-in-real-clinical-practice-results-of-an-italian-observational-study
#1
Roberto Caporali, Luca Idolazzi, Stefano Bombardieri, Gianfranco Ferraccioli, Roberto Gerli, Marco Govoni, Marco Matucci Cerinic, Giovanni Pomponio, Fausto Salaffi, Rossella Tirri, Francesca Benaglio, Laura Bianchino, Piercarlo Sarzi-Puttini
OBJECTIVES: To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice. METHODS: TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion. RESULTS: 322 RA patients were enrolled in 59 Italian centres (mean age: 55...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516881/exploring-the-remission-concept-in-rheumatoid-arthritis-with-patients-and-rheumatologists-time-for-a-new-approach
#2
Carlos Acebes, José Luis Andreu, Alejandro Balsa, Enrique Battle, Javier de Toro-Santos, Francisco García Llorente, María Victoria Hernández, Benjamín Fernández-Gutiérrez, Cristina Hidalgo-Calleja, Lucía Mayordomo, Esperanza Naredo, Francisco Javier Narváez, Ana M Ortiz, José Luis Pablos, Trinidad Pérez-Sandoval, Carlos Rodríguez-Lozano, Olga Sánchez-Pernaute, Jacqueline Usón, José B Negrón, Estibaliz Loza, Loreto Carmona, Susana Gómez Castro, María Montoro Alvarez
OBJECTIVES: To explore the remission concept in rheumatoid arthritis (RA) and to compare remission definitions and related concepts between rheumatologists and patients with the purpose of identifying similarities and disparities to comprehend the different perspectives of the disease. METHODS: This was a qualitative study of discourse and content analysis through focus groups, conducted from February to March 2016. Four focus groups were set up, each one with different interests: rheumatologists involved in basic research (BR), rheumatologists with high specialisation in imaging techniques (IR), clinical rheumatologists (CR), and patients (PA)...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516880/abatacept-therapy-reduces-cd28-cxcr5-follicular-helper-like-t-cells-in-patients-with-rheumatoid-arthritis
#3
Shunsuke Fukuyo, Shingo Nakayamada, Shigeru Iwata, Satoshi Kubo, Kazuyoshi Saito, Yoshiya Tanaka
OBJECTIVES: The characteristics of T cells targeted by abatacept (ABT) in cases of rheumatoid arthritis (RA) are still unknown. The goal of the study was to determine the pathogenicity of T cells and the predictors of therapeutic effects of ABT. METHODS: We analysed the peripheral T cell phenotype of 34 RA patients via flow cytometry. The correlation of the phenotypes of CD4+ T cells with clinical disease activity and change in CD4+ T cell subsets at baseline and 24 weeks after ABT treatment were evaluated...
April 27, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516879/comparison-of-efficacy-of-first-versus-second-line-adalimumab-in-patients-with-rheumatoid-arthritis-experience-of-the-italian-biologics-registries
#4
Veronica Codullo, Florenzo Iannone, Luigi Sinigaglia, Ennio Giulio Favalli, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Gianfranco Ferraccioli, Elisa Gremese, Antonio Carletto, Alessandro Giollo, Marcello Govoni, Francesca Bergossi, Mauro Galeazzi, Luca Cantarini, Fausto Salaffi, Marco Di Carlo, Chiara Bazzani, Raffaele Pellerito, Marco Sebastiani, Roberta Ramonda, Giovanni Lapadula, Roberto Caporali
OBJECTIVES: Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in clinical practice and drug registries give us information to support their use. Adalimumab (ADA) is able to induce a comprehensive disease control in RA by achieving clinical, functional and radiographic control. METHODS: By interrogating 2 Italian registries, LORHEN and GISEA, we analysed the efficacy of ADA in first- or second-line in a total of 2262 RA patients...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28511288/a-tele-health-follow-up-strategy-for-tight-control-of-disease-activity-in-rheumatoid-arthritis-results-of-the-non-inferiority-randomised-controlled-trail-the-tera-study
#5
Annette Thurah, Kristian Stengaard-Pedersen, Mette Axelsen, Ulrich Fredberg, Liv M V Schougaard, Niels H I Hjollund, Mogens Pfeiffer-Jensen, Trine B Laurberg, Ulrik Tarp, Kirsten Lomborg, Thomas Maribo
OBJECTIVE: To test the effect of patient-reported outcome (PRO) based tele-health follow-up for tight control of disease activity in patients with rheumatoid arthritis (RA), and the differences between tele-health follow-up performed by rheumatologists or rheumatology nurses. METHODS: A total of 294 patients were randomized (1:1:1) to either PRO-based tele-health follow-up carried out by a nurse (PRO-TN) or a rheumatologist (PRO-TR), or conventional out-patient follow-up by physicians...
May 16, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28507184/importance-of-obtaining-remission-for-work-productivity-and-activity-of-patients-with-rheumatoid-arthritis
#6
Dam Kim, Yuko Kaneko, Tsutomu Takeuchi
OBJECTIVE: To identify the factors relevant to work and activity impairment in patients with rheumatoid arthritis. METHODS: In total, 1274 consecutive patients were included. Work and activity impairment were measured by the Work Productivity and Activity Impairment questionnaire, and related clinical factors were examined. RESULTS: Work and activity impairment was reported by 67.4% of the patients. Multivariable linear regression analyses revealed pain and non-remission to be associated with activity impairment and presenteeism...
May 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28505163/anti-citrullinated-peptide-antibodies-are-the-strongest-predictor-of-clinically-relevant-radiographic-progression-in-rheumatoid-arthritis-patients-achieving-remission-or-low-disease-activity-a-post-hoc-analysis-of-a-nationwide-cohort-in-japan
#7
Tomohiro Koga, Akitomo Okada, Takaaki Fukuda, Toshihiko Hidaka, Tomonori Ishii, Yukitaka Ueki, Takao Kodera, Munetoshi Nakashima, Yuichi Takahashi, Seiyo Honda, Yoshiro Horai, Ryu Watanabe, Hiroshi Okuno, Toshiyuki Aramaki, Tomomasa Izumiyama, Osamu Takai, Taiichiro Miyashita, Shuntaro Sato, Shin-Ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Tomoki Origuchi, Hideki Nakamura, Kiyoshi Aoyagi, Katsumi Eguchi, Atsushi Kawakami
OBJECTIVES: To determine prognostic factors of clinically relevant radiographic progression (CRRP) in patients with rheumatoid arthritis (RA) achieving remission or low disease activity (LDA) in clinical practice. METHODS: Using data from a nationwide, multicenter, prospective study in Japan, we evaluated 198 biological disease-modifying antirheumatic drug (bDMARD)-naïve RA patients who were in remission or had LDA at study entry after being treated with conventional synthetic DMARDs (csDMARDs)...
2017: PloS One
https://www.readbyqxmd.com/read/28487504/obinutuzumab-is-effective-in-chronic-lymphocytic-leukemia-and-rheumatoid-arthritis-after-rituximab-failure-a-case-report
#8
Curtis Lachowiez, Atul Deodhar, Eliana Kozin, Stephen Spurgeon
BACKGROUND Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting older adults. As such, many of these patients suffer from co-existing disease states, and the provider must take these comorbidities into account when determining a treatment regimen. The widespread use of monoclonal antibodies (mAbs) has drastically changed the treatment landscape of multiple diseases, ranging from leukemia to autoimmune conditions such as rheumatoid arthritis. CASE REPORT We present the case of a patient who had progression of his CLL and rheumatoid symptoms on rituximab therapy, and was subsequently treated with the second-generation anti-CD20 antibody obinutuzumab...
May 10, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28482933/models-solely-using-claims-based-administrative-data-are-poor-predictors-of-rheumatoid-arthritis-disease-activity
#9
Brian C Sauer, Chia-Chen Teng, Neil A Accortt, Zachary Burningham, David Collier, Mona Trivedi, Grant W Cannon
BACKGROUND: This study developed and validated a claims-based statistical model to predict rheumatoid arthritis (RA) disease activity, measured by the 28-joint count Disease Activity Score (DAS28). METHOD: Veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry with one year of data available for review before being assessed by the DAS28, were studied. Three models were developed based on initial selection of variables for analyses. The first model was based on clinically defined variables, the second leveraged grouping systems for high dimensional data and the third approach prescreened all possible predictors based on a significant bivariate association with the DAS28...
May 8, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28481462/biologics-or-tofacitinib-for-people-with-rheumatoid-arthritis-naive-to-methotrexate-a-systematic-review-and-network-meta-analysis
#10
REVIEW
Jasvinder A Singh, Alomgir Hossain, Amy S Mudano, Elizabeth Tanjong Ghogomu, Maria E Suarez-Almazor, Rachelle Buchbinder, Lara J Maxwell, Peter Tugwell, George A Wells
BACKGROUND: Biologic disease-modifying anti-rheumatic drugs (biologics) are highly effective in treating rheumatoid arthritis (RA), however there are few head-to-head biologic comparison studies. We performed a systematic review, a standard meta-analysis and a network meta-analysis (NMA) to update the 2009 Cochrane Overview. This review is focused on the adults with RA who are naive to methotrexate (MTX) that is, receiving their first disease-modifying agent. OBJECTIVES: To compare the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib versus comparator (methotrexate (MTX)/other DMARDs) in people with RA who are naive to methotrexate...
May 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28480094/validation-of-leiden-score-in-predicting-progression-of-rheumatoid-arthritis-in-undifferentiated-arthritis-in-indian-population
#11
K Ghosh, A Chatterjee, S Ghosh, S Chakraborty, P Chattopadhyay, A Bhattacharya, M Pal
BACKGROUND: Leiden Score, is a very useful tool for predicting future development of rheumatoid arthritis (RA), among undifferentiated arthritis (UA) patients. This score has been validated in various western studies but rarely among south east Asian patients. AIMS: To validate the Leiden early arthritis prediction rule in an Indian cohort of patients for predicting rheumatoid arthritis (RA) in undifferentiated arthritis (UA) patients and to formulate any simpler version of prediction score taking only clinical variables of original Leiden prediction rule...
July 2016: Annals of Medical and Health Sciences Research
https://www.readbyqxmd.com/read/28463029/high-rate-of-improvement-in-serum-matrix-metalloproteinase-3-levels-at-4-weeks-predicts-remission-at-52-weeks-in-ra-patients-treated-with-adalimumab
#12
Yosuke Hattori, Toshihisa Kojima, Atsushi Kaneko, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Yuichiro Yabe, Takeshi Oguchi, Yasuhide Kanayama, Hiroyuki Miyake, Takefumi Kato, Hideki Takagi, Masatoshi Hayashi, Takayasu Ito, Tomone Shioura, Nobunori Takahashi, Hisato Ishikawa, Koji Funahashi, Naoki Ishiguro
OBJECTIVE: This study aimed to determine whether serum matrix metalloproteinase-3 (MMP-3) levels can predict remission in rheumatoid arthritis (RA) patients treated with adalimumab (ADA). METHODS: Subjects were 114 RA patients continuously treated with ADA for 52 weeks. Predictive factors at baseline and 4 weeks after initiation of ADA therapy for the achievement of remission (28-point count Disease Activity Score-CRP (DAS28-CRP) < 2.3) at 52 weeks were evaluated by multivariate logistic regression analysis...
May 2, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28451787/future-therapeutic-targets-in-rheumatoid-arthritis
#13
REVIEW
Tommy Tsang Cheung, Iain B McInnes
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment. With the implementation of treat-to-target strategies and availability of biologic therapies, the outcomes for patients with RA have significantly improved. However, the unmet need in the treatment of RA remains high as some patients do not respond sufficiently to the currently available agents, remission is not always achieved and refractory disease is not uncommon...
April 27, 2017: Seminars in Immunopathology
https://www.readbyqxmd.com/read/28448562/the-impact-of-anti-drug-antibodies-on-drug-concentrations-and-clinical-outcomes-in-rheumatoid-arthritis-patients-treated-with-adalimumab-etanercept-or-infliximab-results-from-a-multinational-real-world-clinical-practice-non-interventional-study
#14
Robert J Moots, Ricardo M Xavier, Chi Chiu Mok, Mahboob U Rahman, Wen-Chan Tsai, Mustafa H Al-Maini, Karel Pavelka, Ehab Mahgoub, Sameer Kotak, Joan Korth-Bradley, Ron Pedersen, Linda Mele, Qi Shen, Bonnie Vlahos
OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes. METHODS: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX...
2017: PloS One
https://www.readbyqxmd.com/read/28446212/doctors-preferences-in-de-escalating-dmards-in-rheumatoid-arthritis-a-discrete-choice-experiment
#15
T Martijn Kuijper, Riëtte Folmer, Elly A Stolk, Johanna M W Hazes, Jolanda J Luime
BACKGROUND: Current guidelines suggest reduction of DMARDs can be considered in RA patients in remission. Objectives were (1) to estimate the relative importance of patient characteristics rheumatologists consider in their decision to de-escalate (2) to assess whether heterogeneity exists among rheumatologists with respect to de-escalation and (3) to identify the preferred de-escalation strategy. METHODS: A discrete choice experiment (DCE) was conducted. All rheumatologists and trainees in The Netherlands were invited to participate...
April 26, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28439423/rheumatoid-arthritis-what-do-mri-and-ultrasound-show
#16
EDITORIAL
Iwona Sudoł-Szopińska, Lennart Jans, James Teh
Rheumatoid arthritis is the most common inflammatory arthritis, affecting approximately 1% of the world's population. Its pathogenesis has not been completely understood. However, there is evidence that the disease may involve synovial joints, subchondral bone marrow as well as intra- and extraarticular fat tissue, and may lead to progressive joint destruction and disability. Over the last two decades, significant improvement in its prognosis has been achieved owing to new strategies for disease management, the emergence of new biologic therapies and better utilization of conventional disease-modifying antirheumatic drugs...
March 2017: Journal of Ultrasonography
https://www.readbyqxmd.com/read/28431485/efficacy-of-golimumab-in-belgian-patients-with-active-rheumatoid-arthritis-despite-treatment-with-non-biologic-disease-modifying-anti-rheumatic-drugs-sub-analysis-of-the-go-more-study
#17
Patrick Durez, Marie Vanthuyne, Muhammad S Soyfoo, Ilse Hoffman, Michel Malaise, Piet Geusens
OBJECTIVES: The GO-MORE trial (NCT00975130) was a phase 3 study in 40 countries evaluating the efficacy and safety of golimumab as add-on therapy in biologic-naïve adults with active rheumatoid arthritis despite stable treatment with disease-modifying anti-rheumatic drugs. To inform local practice in Belgium and examine the role of baseline disease activity in treatment response, we compared the efficacy of golimumab in the Belgian subpopulation and the rest of the world. METHODS: Baseline disease activity and six-month efficacy rates in the GO-MORE trial were compared for the Belgian subpopulation and the rest of the world by t-tests and chi-squared tests...
April 21, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/28431141/grade-and-location-of-power-doppler-are-predictive-of-damage-progression-in-rheumatoid-arthritis-patients-in-clinical-remission-by-anti-tumour-necrosis-factor-%C3%AE
#18
Bernd Raffeiner, Enrico Grisan, Costantino Botsios, Roberto Stramare, Gaia Rizzo, Livio Bernardi, Leonardo Punzi, Francesca Ometto, Andrea Doria
Objectives.: To investigate power Doppler (PD) signal, grade and location and their association with radiographic progression in RA patients in remission. Methods: . A prospective observational study was conducted in 125 consecutive RA patients in stable 28-joint DAS (DAS28) remission (⩾6 months) achieved on anti-TNF-α. At baseline, patients in stable remission underwent radiographic and US examination of the wrists and MCP, PIP and MTP joints. Semi-quantitative PD scoring (0-3) was recorded...
April 20, 2017: Rheumatology
https://www.readbyqxmd.com/read/28420837/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-with-six-months-of-biological-dmards-treatment
#19
Yusuke Miwa, Ryo Takahashi, Yuzo Ikari, Airi Maeoka, Shinichiro Nishimi, Nao Oguro, Tomoki Hayashi, Mika Hatano, Sakiko Isojima, Ryo Yanai, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki, Kenji Sanada
Objective Although previous studies have reported the prognostic factors for functional remission, no reports have cited the predictive factors. Our aim was to study the predictive factors for functional remission, which is a treatment goal in rheumatoid arthritis (RA), after receiving biological disease-modifying antirheumatic drugs (bDMARDs) treatment for six months. Methods The study consisted of 333 RA patients treated with bDMARDs for six months. The following patient characteristics were investigated: age, gender, disease duration, type of bDMARDs, baseline steroid and methotrexate dosage, and levels of serum rheumatoid factor, matrix metalloprotease, anti-cyclic citrullinated peptides antibody, tumor necrosis factor-α, and interleukin-6...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28420375/silent-progression-in-patients-with-rheumatoid-arthritis-is-das28-remission-an-insufficient-goal-in-ra-results-from-the-german-remission-plus-cohort
#20
Philipp Sewerin, Stefan Vordenbaeumen, Annika Hoyer, Ralph Brinks, Christian Buchbender, Falk Miese, Christoph Schleich, Sabine Klein, Matthias Schneider, Benedikt Ostendorf
BACKGROUND: Remission is arguably the ultimate therapeutic goal in rheumatoid arthritis (RA). Applying modern strategies, clinical remission can be achieved in a substantial number of patients with early RA (ERA). Even in those patients, the number and scope of erosions can increase. We, therefore, investigated the value of MRI for the detection of radiological progression in patients with DAS28 improvement and/or clinical remission of the German Remission-plus cohort. METHODS: Data-sets of 80 RA patients (according to 2010 ACR/EULAR criteria) from the Remission-plus study cohort, who fulfilled the following criteria, were retrospectively analysed: availability of two consecutive MRI scans (low-field MRI, follow-up interval 1 year) of the clinically dominant hand and wrist, and the presence of DAS28 (CRP) scores at both time points, which was used to assess disease activity...
April 19, 2017: BMC Musculoskeletal Disorders
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"